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• Pre-defined biological pathways !": $ = 1,2,⋯ , * were 
downloaded from KEGG, where !" is the set of genes in pathway k.
• The + patients were clustered using expression levels of genes 
from each pathway separately based on a Gaussian Mixture Model. 
Let ," = -.", -/",⋯ , -0" be the clustering results of the patients 
using pathway !", in which -1" is an integer indicating which cluster 
the patient 2 is assigned to by pathway !". 
•The clustering results across all the pathways were summarized 
into a pathway based distance score defined as follows. The 
distance between patient 2. and 2/ is calculated as3 2., 2/ = #{$: -16" ≠ -18" ,9" > 1}#{$:9" > 1}
where 9" is the total number of patient clusters identified using 
pathway !" and #{⋅} is the size of the set {⋅}.
• To demonstrate our method, we simulate gene expression data 
from 120 patients that belong to 3 groups with 40 patients per 
group. The expression levels of genes from pathway !" are 
simulated from the following distribution:(>?@A>? @A)~>DEFFGDH( IJK0 , Σ = (ΣN OΠOΠ Σ. ))
where Ω" is the set of genes from pathway !" that are differentially 
expressed across the 3 groups, >?@A is the vector of expression 
levels of the genes from Ω" in subject G, ,? indicates which group 
subject G belongs to, IJK = R−T, GU ,? = 10, GU ,? = 2T, GU ,? = 3 , ΣN = W/ ⋯ O⋮ ⋱ ⋮O ⋯ W/ , W/ = 1 +
/[8\ , ]. = ^W/ ⋯ O⋮ ⋱ ⋮O ⋯ ^W/ and Π = 1 ⋯ 1⋮ ⋱ ⋮1 ⋯ 1 . 
•Meaning of of simulation parameters:
• ^ represents the background noise of genes that are not 
differentially expressed.
• T represents the amount of differences in the gene 
expression profiles between the 3 groups.
• O represents the correlation coefficient between genes in the 
same pathway.
• _` represents the proportion of genes in a pathway that are 
differentially expressed.
• Our method was compared to Pathifier and the traditional 
Euclidean distance.
• We have developed a novel distance to represent 
the biological difference between samples using gene 
expression data.
•The comparison of this distance score to the 
Euclidean distance showed a better performance in 
both identifying the true number of clusters and 
assigning the samples to the correct classes.
• The comparison of this score to Pathifier showed a 
better performance and robustness for pathways with 
a small number of genes. 
• Ongoing work on using a regularized Gaussian 
Mixture Model for clustering using each pathway.
METHODS
BACKGROUND
• Unsupervised clustering of patients using gene expression data  is 
popularly used to study disease heterogeneity.
• Traditional Euclidean distance may not be efficient at 
discriminating the biological differences between samples due to the 
high noise to signal ratio in gene expression data.
• Distance scores defined based on pre-defined pathways instead of 
individual genes may help reduce the noise to signal ratio and 
integrate prior biological knowledge.
• We assume that differences in the expression levels of genes from 
the same pathway are more predictive of the biological differences 
compared to standard approach and if integrated into clustering 
analysis, will enhance the robustness and accuracy of the clustering 
results.
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CONCLUSIONS
RESULTS Distance matrices comparison on asthma gene expression 
data
Simulation (low dimension): Connectivity criteria comparison (a = b) for B=1 and 3.
Simulation (high dimension): Connectivity 
criteria (a = b) for B=1 and 3. Accuracy of identifying the true number of clusters fcd a ≠ b.
e 0.5 0.6 0.7 0.8 0.9 1.0 1.1 1.2 1.3 1.4 1.5
HC
Euclid All 13% 13% 10% 8% 7% 7% 2% 6% 1% 10% 7%
Euclid KEGG 6% 8% 2% 3% 4% 2% 3% 19% 35% 55% 72%
PBS KEGG 22% 37% 34% 38% 45% 61% 75% 89% 98% 99% 100%
Kmeans
Euclid All 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0%
Euclid KEGG 0% 0% 0% 0% 0% 0% 3% 19% 39% 54% 77%
PBS KEGG 19% 50% 77% 92% 97% 97% 100% 100% 100% 99% 100%
Accuracy rate of identifying the true number of clusters for a = b,f = g and hi = b. k.
Euclid_all Euclid_KEGG KEGG_dist Pathifier_KEGG
Age at Visit (years) 0.65 0.37 0.32 0.28
Gender 0.02* 0.14 0.58 0.28
History of Atopy - N (%) 0.89 0.2 0.02 0.62
Age of Symptom Onset 0.55 0.25 0.17 0.62
Disease Duration (years) 0.98 0.9 0.67 0.38
History of Hospitalization - N (%) 0.21 0.77 0.04 1.00
History of Intubations - N (%) 0.14 0.12 0.05 0.04
OCS tapers in past year- N (%) 0.65 1.00 0.67 0.83
ACT Score 0.25 0.41 0.22 0.56
FEV1- % of predicted value
Pre β2 agonist use 0.04 0.02 0.02 0.04
Post β2 agonist use 0.06 0.05* 0.06 0.06
FVC- % of predicted value
Pre β2 agonist use 0.04 0.02 0.04 0.03
Post β2 agonist use 0.12 0.06 0.16 0.13
FEV1/FVC- % of predicted value
Pre β2 agonist use 0.23 0.46 0.13 0.41
Post β2 agonist use 0.14 0.2 0.06 0.09
BDR (%) 0.27 0.05 0.05 0.09
FENO (ppb) 0.05* 0.54 0.27 0.40
Phenotypic and physiologic characteristics of the identified 
clusters
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